These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8922192)

  • 1. 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma.
    Betticher DC; Zucca E; von Rohr A; Egger T; Radford JA; Ambrosetti A; Bürki K; Rufener B; Schmitz SF; Cerny T
    Ann Oncol; 1996 Oct; 7(8):793-9. PubMed ID: 8922192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
    Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
    J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
    Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
    Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
    Piro LD; Carrera CJ; Carson DA; Beutler E
    N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
    Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
    J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research].
    Sperb RA; von Rohr A; Ratschiller D; Bacchi M; Tichelli A; Hess U; Cerny T; Tobler A; Betticher DC
    Schweiz Med Wochenschr; 1998 Oct; 128(42):1593-7. PubMed ID: 9824888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
    Saven A; Emanuele S; Kosty M; Koziol J; Ellison D; Piro L
    Blood; 1995 Sep; 86(5):1710-6. PubMed ID: 7655003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
    Tefferi A; Witzig TE; Reid JM; Li CY; Ames MM
    J Clin Oncol; 1994 Mar; 12(3):569-74. PubMed ID: 8120555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases.
    Robak T; Błasińska-Morawiec M; Krykowski E; Hellmann A; Lewandowski K; Dmoszyńska A; Adamczyk-Cioch M; Kazimierczak M; Trepińska E; Dwilewicz-Trojaczek M; Kuratowska Z; Skotnicki AB; Nowak WS; Zdziarska B; Urasiński I
    Eur J Haematol; 1997 Oct; 59(4):216-20. PubMed ID: 9338619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
    Estey EH; Kurzrock R; Kantarjian HM; O'Brien SM; McCredie KB; Beran M; Koller C; Keating MJ; Hirsch-Ginsberg C; Huh YO
    Blood; 1992 Feb; 79(4):882-7. PubMed ID: 1346577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
    Canfield VA; Vose J; Guiney P; Bennett B; Nichols C
    Leuk Lymphoma; 1997 Jan; 24(3-4):335-9. PubMed ID: 9156663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
    Saven A; Carrera CJ; Carson DA; Beutler E; Piro LD
    Blood; 1992 Aug; 80(3):587-92. PubMed ID: 1353380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
    Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
    Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-CdA in the treatment of hairy cell leukaemia.
    Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
    J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.